Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx has begun Phase 1b trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin administered in combination with the commonly used chemotherapeutic agent doxorubicin.
Subscribe to our email newsletter
The single-center trial of aldoxorubicin, a tumor-targeting conjugate of doxorubicin, is designed to enroll up to 24 patients with advanced solid tumors who have failed other therapies.
Doxorubicin will be administered at 50% of its maximum tolerated dose in combination with escalating doses of aldoxorubicin to determine the maximum tolerated dose of the combination of these two drugs in the patient population.
CytRx CEO Steven Kriegsman said Dr. Chawla led Phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors and presented clinical results from the trial at the American Society of Clinical Oncology (ASCO) conference.
"He also is leading our global Phase 2b clinical trial designed to compare aldoxorubicin head-to-head with doxorubicin as a first-line treatment for patients with advanced soft tissue sarcoma. Enrollment completion and data analysis are expected for this trial in 2013," Dr. Chawla added.